Aldatu’s affordable drug resistance diagnostics matches HIV patients with effective drugs and saves resource-limited healthcare systems money.

Find Out More >>

HIV minor variants

Aldatu Biosciences Awarded $3 Million NIH SBIR Contract for Early HIV Drug Resistance Detection

October 15th, 2018
Read More >>

Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board
August 3rd, 2017
In Memory of Mark Wainberg: Aldatu Advisor and HIV Pioneer
April 13th, 2017
Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic Development
February 7th, 2017
Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit Corporation
June 3rd, 2016

Aldatu Biosciences Awarded $3 Million NIH SBIR Contract for Early HIV Drug Resistance Detection

Aldatu Biosciences Awarded $3 Million NIH SBIR Contract for Early HIV Drug Resistance Detection

October 15th, 2018

Read More >>

Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board
August 3rd, 2017
In Memory of Mark Wainberg: Aldatu Advisor and HIV Pioneer
April 13th, 2017
Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic Development
February 7th, 2017
Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit Corporation
June 3rd, 2016